A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy


      Objective: Treatment with heparin and low-dose aspirin improves fetal survival among women with antiphospholipid syndrome. Despite treatment, however, these pregnancies are frequently complicated by preeclampsia, fetal growth restriction, and placental insufficiency, often with the result of preterm birth. Small case series suggest that intravenous immune globulin may reduce the rates of these obstetric complications, but the efficacy of this treatment remains unproven. This pilot study was undertaken to determine the feasibility of a multicenter trial of intravenous immune globulin and to assess the impact on obstetric and neonatal outcomes among women with antiphospholipid syndrome of the addition of intravenous immune globulin to a heparin and low-dose aspirin regimen. Study Design: This multicenter, randomized, double-blind pilot study compared treatment with heparin and low-dose aspirin plus intravenous immune globulin with heparin and low-dose aspirin plus placebo in a group of women who met strict criteria for antiphospholipid syndrome. All patients had lupus anticoagulant, medium to high levels of immunoglobulin G anticardiolipin antibodies, or both. Patients with a single live intrauterine fetus at ≤12 weeks’ gestation were randomly assigned to receive either intravenous immune globulin (1 g/kg body weight) or an identical-appearing placebo for 2 consecutive days each month until 36 weeks’ gestation in addition to a heparin and low-dose aspirin regimen. Maternal characteristics, obstetric complications, and neonatal outcomes were compared with the Student t test and the Fisher exact test as appropriate. Results: Sixteen women were enrolled during a 2-year period; 7 received intravenous immune globulin and 9 were given placebo. The groups were similar with respect to age, gravidity, number of previous pregnancy losses, and gestational age at the initiation of treatment. Obstetric outcomes were excellent in both groups, with all women being delivered of live-born infants after 32 weeks’ gestation. The rates of antepartum complications such as preeclampsia, fetal growth restriction, and placental insufficiency (as manifested by fetal growth restriction or fetal distress) were similar between the 2 groups. Gestational age at delivery (intravenous immune globulin group, 34.6 ± 1.1 weeks; placebo group, 36.7 ± 2.1 weeks) and birth weights (intravenous immune globulin group, 2249.7 ± 186.1 g; placebo group; 2604.4 ± 868.9 g) were similar between the 2 groups. There were fewer cases of fetal growth restriction (intravenous immune globulin group, 0%; placebo group, 33%) and neonatal intensive care unit admission (intravenous immune globulin group, 20%; placebo group, 44%) among the infants in the intravenous immune globulin group than those in the placebo group, but these differences were not significant. Conclusion: A multicenter treatment trial of intravenous immune globulin is feasible. In this pilot study intravenous immune globulin did not improve obstetric or neonatal outcomes beyond those achieved with a heparin and low-dose aspirin regimen. Although not statistically significant, the findings of fewer cases of fetal growth restriction and neonatal intensive care unit admissions among the intravenous immune globulin–treated pregnancies may warrant expansion of the study. (Am J Obstet Gynecol 2000;182:122-7.)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lockshin MD
        Antiphospholipid antibody. Babies, blood clots, biology [clinical conference].
        JAMA. 1997; 277: 1549-1551
        • Asherson RA
        • Khamashta MA
        • Ordi-Ros J
        • Derksen RH
        • Machin SJ
        • Barquinero J
        • et al.
        The “primary” antiphospholipid syndrome: major clinical and serological features.
        Medicine (Baltimore). 1989; 68: 366-374
        • Rai R
        • Cohen H
        • Dave M
        • Regan L
        Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).
        BMJ. 1997; 314: 253-257
        • Kutteh WH
        Antiphospholipid antibody–associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.
        Am J Obstet Gynecol. 1996; 174: 1584-1589
        • Branch DW
        • Silver RM
        • Blackwell JL
        • Reading JC
        • Scott JR
        Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.
        Obstet Gynecol. 1992; 80: 614-620
        • American College of Obstetricians and Gynecologists
        Antiphospholipid syndrome. 1998 Feb. ACOG Educational Bulletin No. 244.
        Int J Gynaecol Obstet. 1998; 61: 193-202
        • Lima F
        • Khamashta MA
        • Buchanan NM
        • Kerslake S
        • Hunt BJ
        • Hughes GR
        A study of sixty pregnancies in patients with the antiphospholipid syndrome.
        Clin Exp Rheumatol. 1996; 14: 131-136
        • Katz VL
        • Thorp Jr, JM
        • Watson WJ
        • Fowler L
        • Heine RP
        Human immunoglobulin therapy for preeclampsia associated with lupus anticoagulant and anticardiolipin antibody.
        Obstet Gynecol. 1990; 76: 986-988
        • Scott JR
        • Branch DW
        • Kochenour NK
        • Ward K
        Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization.
        Am J Obstet Gynecol. 1988; 159: 1055-1056
        • Spinnato JA
        • Clark AL
        • Pierangeli SS
        • Harris EN
        Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy.
        Am J Obstet Gynecol. 1995; 172: 690-694
        • Oshiro BT
        • Silver RM
        • Scott JR
        • Yu H
        • Branch DW
        Antiphospholipid antibodies and fetal death.
        Obstet Gynecol. 1996; 87: 489-493
        • Wilson WA
        • Gharavi AE
        • Koike T
        • Lockshin MD
        • Branch DW
        • Piette JC
        • et al.
        International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.
        Arthritis Rheum. 1999; 42: 1309-1311
        • National High Blood Pressure Education Program Working Group
        Report on High Blood Pressure in Pregnancy.
        Am J Obstet Gynecol. 1990; 163: 1691-1712
        • Newburger JW
        • Takahashi M
        • Burns JC
        • Beiser AS
        • Chung KJ
        • Duffy CE
        • et al.
        The treatment of Kawasaki syndrome with intravenous gamma globulin.
        N Engl J Med. 1986; 315: 341-347
        • Jordan SC
        • Toyoda M
        Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin.
        Clin Exp Immunol. 1994; 97: 31-38
        • Bussel JB
        Neonatal uses of intravenous immunoglobulin.
        Am J Pediatr Hematol Oncol. 1990; 12: 505-509
        • Kumar A
        • Loiwal V
        • Gupta P
        Autoimmune neonatal thrombocytopenia (AINT) successfully managed with intravenous immunoglobulins (IVIg).
        Indian Pediatr. 1997; 34: 63-65
        • Bussel JB
        • Hilgartner MW
        The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease.
        Br J Haematol. 1984; 56: 1-7
        • Clark AL
        • Branch DW
        • Silver RM
        • Harris EN
        • Pierangeli S
        • Spinnato JA
        Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.
        Obstet Gynecol. 1999; 93: 437-441
        • Khoshnood B
        • Lee KS
        • Corpuz M
        • Koetting M
        • Hsieh HI
        • Kim BI
        Models for determining cost of care and length of stay in neonatal intensive care units.
        Int J Technol Assess Health Care. 1996; 12: 62-71
        • Harris EN
        • Hughes GR
        • Gharavi AE
        Anti-cardiolipin antibodies and the lupus anticoagulant.
        Clin Exp Rheumatol. 1986; 4: 187-190